We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwar
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
GH Research | 6-K: Report of foreign private issuer (related to financial reporting)
Buy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestones
GH Research Is Maintained at Buy by Canaccord Genuity
GH Research Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $31
Express News | GH Research PLC : Canaccord Genuity Raises Target Price to $31 From $30
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)
Express News | GH Research PLC - Phase 2a Clinical Trial of GH001 in Postpartum Depression on Track for Expected Completion in Q3 2024
Express News | GH Research - Cash, Cash Equivalents, Other Financial Assets and Marketable Securities of $214.0 Mln Expected to Provide Cash Runway Into 2026
Express News | GH Research PLC Q1 EPS USD -0.15
GH Research: Cash Runway Into 2026 >GHRS
GH Research: Cash Runway Into 2026 >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c